GOG-3020/CO-338-087: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Grants and Contracts Details


Human Clinical Study - CONFIDENTIAL This is a randomized, mulitnational, double blind, dual placebo controlled, 4-arm, phase 3 sudy evaluating rucaparib and nivolumab as monotherapy and in comination as maintenance treatment foloowing response to front line treatment (surgery and platinum-based chemotherapy) in newly diagnosed ovarian cancer patients. The sutdy will enroll patients with high grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who achience a response to their first platinum based regimen. This study consists of a screening phase, a treatment phase, and a post treatment phase.
Effective start/end date11/30/1812/18/24


  • Gynecological Oncology Group Foundation Incorporated: $269,146.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.